IL129300A - Liquid pharmaceutical composition comprising an hiv protease inhibitor or a combination of hiv protease inhibitors in a pharmaceutically acceptable organic solvent - Google Patents
Liquid pharmaceutical composition comprising an hiv protease inhibitor or a combination of hiv protease inhibitors in a pharmaceutically acceptable organic solventInfo
- Publication number
- IL129300A IL129300A IL12930097A IL12930097A IL129300A IL 129300 A IL129300 A IL 129300A IL 12930097 A IL12930097 A IL 12930097A IL 12930097 A IL12930097 A IL 12930097A IL 129300 A IL129300 A IL 129300A
- Authority
- IL
- Israel
- Prior art keywords
- hiv protease
- combination
- pharmaceutically acceptable
- pharmaceutical composition
- organic solvent
- Prior art date
Links
- 239000004030 hiv protease inhibitor Substances 0.000 title 2
- 229940122440 HIV protease inhibitor Drugs 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
- 239000003960 organic solvent Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75439096A | 1996-11-21 | 1996-11-21 | |
PCT/US1997/020794 WO1998022106A1 (en) | 1996-11-21 | 1997-11-12 | Pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
IL129300A0 IL129300A0 (en) | 2000-02-17 |
IL129300A true IL129300A (en) | 2003-07-06 |
Family
ID=25034589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12930097A IL129300A (en) | 1996-11-21 | 1997-11-12 | Liquid pharmaceutical composition comprising an hiv protease inhibitor or a combination of hiv protease inhibitors in a pharmaceutically acceptable organic solvent |
Country Status (26)
Country | Link |
---|---|
EP (2) | EP0942721B1 (pt) |
JP (2) | JP3592337B2 (pt) |
KR (2) | KR100478075B1 (pt) |
CN (3) | CN1250219C (pt) |
AR (2) | AR010634A1 (pt) |
AT (1) | ATE231393T1 (pt) |
AU (1) | AU717546B2 (pt) |
BG (1) | BG64411B1 (pt) |
BR (1) | BR9714310A (pt) |
CA (2) | CA2505430A1 (pt) |
CZ (1) | CZ299728B6 (pt) |
DE (1) | DE69718668T2 (pt) |
DK (1) | DK0942721T3 (pt) |
ES (1) | ES2191862T3 (pt) |
HK (1) | HK1053787A1 (pt) |
HU (1) | HU224319B1 (pt) |
IL (1) | IL129300A (pt) |
NO (1) | NO326927B1 (pt) |
NZ (1) | NZ335002A (pt) |
PL (1) | PL190185B1 (pt) |
PT (1) | PT942721E (pt) |
SK (1) | SK285022B6 (pt) |
TR (1) | TR199901129T2 (pt) |
TW (1) | TW475895B (pt) |
WO (1) | WO1998022106A1 (pt) |
ZA (1) | ZA9710071B (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
RU2202346C2 (ru) * | 1997-07-29 | 2003-04-20 | Фармация Энд Апджон Компани | Фармацевтическая композиция для кислотных липофильных соединений в форме самоэмульгирующейся композиции |
KR100509130B1 (ko) * | 1997-07-29 | 2005-08-18 | 파마시아 앤드 업존 캄파니 엘엘씨 | 친지성 화합물의 자가유화 제제 |
RU2211021C2 (ru) * | 1997-07-29 | 2003-08-27 | Фармация Энд Апджон Компани | Фармацевтическая самоэмульгирующая композиция и ее носитель для липофильных фармацевтически активных агентов |
US6894171B1 (en) | 1998-07-20 | 2005-05-17 | Abbott Laboratories | Polymorph of a pharmaceutical |
MY145265A (en) * | 1998-07-20 | 2012-01-13 | Abbott Lab | Amorphous ritonavir |
EP1712231A3 (en) * | 1998-11-04 | 2007-11-21 | Pharmacia & Upjohn Company LLC | Method for improving the pharmacokinetics of tipranavir |
CN1154491C (zh) * | 1998-11-04 | 2004-06-23 | 法玛西雅厄普约翰美国公司 | 用于改善替普拉那维的药物动力学的方法 |
US6956048B2 (en) | 1999-03-31 | 2005-10-18 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
US7141593B1 (en) | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
JP4753511B2 (ja) * | 1999-06-04 | 2011-08-24 | アボット・ラボラトリーズ | 改良された医薬製剤 |
DE60028754T2 (de) * | 1999-11-12 | 2007-05-31 | Abbott Laboratories, Abbott Park | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
JP2003516345A (ja) * | 1999-12-09 | 2003-05-13 | アルザ・コーポレーション | 抗ウイルス剤 |
JP4769400B2 (ja) | 2000-01-19 | 2011-09-07 | アボット・ラボラトリーズ | 改良された医薬配合物 |
AU2001259817A1 (en) | 2000-05-04 | 2001-11-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health | Methods of and compounds for inhibiting calpains |
US6911214B2 (en) | 2000-09-05 | 2005-06-28 | Abbott Laboratories | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
CA2448438A1 (en) * | 2001-05-25 | 2002-12-05 | Abbott Laboratories | Soft elastic capsules comprising ritonavir and/or lopinavir |
BR0202252A (pt) * | 2002-06-12 | 2004-06-29 | Cristalia Prod Quimicos Farm | Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease |
BR0302424A (pt) * | 2003-07-23 | 2005-03-29 | Cristalia Prod Quimicos Farm | Composição farmacêutica com biodisponibilidade ampliada adequada à adiministração oral de inibidores da protease retroviral. processo de preparação de composição farmacêutica concentrada contendo inibidor da protease retroviral |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
BRPI0401742B8 (pt) | 2004-05-13 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir |
ES2402552T3 (es) * | 2004-07-06 | 2013-05-06 | Abbott Laboratories | Profármacos de inhibidores de proteasa de VIH |
MY153288A (en) * | 2006-06-28 | 2015-01-29 | Hovid Berhad | An effective pharmaceutical carrier for poorly bioavailable drugs |
EP2714683A4 (en) | 2011-05-27 | 2014-11-05 | Hetero Research Foundation | RITONAVIR AMORPH CO-PRECIPITATION |
RU2014148964A (ru) | 2012-05-03 | 2016-06-27 | Сипла Лимитед | Антиретровирусная композиция |
US20130302414A1 (en) * | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
SI2909205T1 (sl) | 2012-10-19 | 2017-02-28 | Bristol-Myers Squibb Company | 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06505963A (ja) * | 1990-11-19 | 1994-07-07 | モンサント カンパニー | レトロウイルスプロテアーゼ阻害剤 |
EP0607334B1 (en) * | 1991-10-11 | 1997-07-30 | The Du Pont Merck Pharmaceutical Company | Cyclic ureas and analogues useful as retroviral protease inhibitiors |
US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
ATE163926T1 (de) * | 1991-11-08 | 1998-03-15 | Merck & Co Inc | Hiv-protease-inhibitoren verwendbar in der aids- behandlung |
AU4253193A (en) * | 1992-05-20 | 1993-12-13 | G.D. Searle & Co. | Urea-containing hydroxyethylamine compounds as retroviral protease inhibitors |
IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
PT727419E (pt) * | 1992-12-29 | 2002-08-30 | Abbott Lab | Compostos intermediarios para a preparacao de inibidores da protease retroviral |
IL110752A (en) * | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
IL111991A (en) * | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5646180A (en) * | 1995-12-05 | 1997-07-08 | Vertex Pharmaceuticals Incorporated | Treatment of the CNS effects of HIV |
US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
-
1997
- 1997-11-07 ZA ZA9710071A patent/ZA9710071B/xx unknown
- 1997-11-12 KR KR10-1999-7004469A patent/KR100478075B1/ko not_active IP Right Cessation
- 1997-11-12 ES ES97947510T patent/ES2191862T3/es not_active Expired - Lifetime
- 1997-11-12 EP EP97947510A patent/EP0942721B1/en not_active Expired - Lifetime
- 1997-11-12 NZ NZ335002A patent/NZ335002A/en not_active IP Right Cessation
- 1997-11-12 AU AU52573/98A patent/AU717546B2/en not_active Expired
- 1997-11-12 CN CNB971997802A patent/CN1250219C/zh not_active Expired - Lifetime
- 1997-11-12 CZ CZ0160299A patent/CZ299728B6/cs not_active IP Right Cessation
- 1997-11-12 CN CNA2006101019049A patent/CN101103984A/zh active Pending
- 1997-11-12 TR TR1999/01129T patent/TR199901129T2/xx unknown
- 1997-11-12 IL IL12930097A patent/IL129300A/xx not_active IP Right Cessation
- 1997-11-12 BR BR9714310-3A patent/BR9714310A/pt active IP Right Grant
- 1997-11-12 AT AT97947510T patent/ATE231393T1/de active
- 1997-11-12 WO PCT/US1997/020794 patent/WO1998022106A1/en not_active Application Discontinuation
- 1997-11-12 JP JP52375198A patent/JP3592337B2/ja not_active Expired - Lifetime
- 1997-11-12 PL PL97336980A patent/PL190185B1/pl unknown
- 1997-11-12 SK SK655-99A patent/SK285022B6/sk not_active IP Right Cessation
- 1997-11-12 PT PT97947510T patent/PT942721E/pt unknown
- 1997-11-12 HU HU0002932A patent/HU224319B1/hu active IP Right Grant
- 1997-11-12 CN CN200510128757XA patent/CN1989963B/zh not_active Expired - Lifetime
- 1997-11-12 EP EP02011533A patent/EP1283041A1/en not_active Withdrawn
- 1997-11-12 CA CA002505430A patent/CA2505430A1/en not_active Abandoned
- 1997-11-12 DE DE69718668T patent/DE69718668T2/de not_active Expired - Lifetime
- 1997-11-12 CA CA002271196A patent/CA2271196C/en not_active Expired - Lifetime
- 1997-11-12 DK DK97947510T patent/DK0942721T3/da active
- 1997-11-12 KR KR10-2003-7006036A patent/KR100516567B1/ko not_active IP Right Cessation
- 1997-11-17 TW TW086117136A patent/TW475895B/zh active
- 1997-11-20 AR ARP970105444A patent/AR010634A1/es active IP Right Grant
-
1999
- 1999-05-20 NO NO19992427A patent/NO326927B1/no not_active IP Right Cessation
- 1999-05-21 BG BG103425A patent/BG64411B1/bg unknown
-
2000
- 2000-03-17 HK HK03104467.3A patent/HK1053787A1/zh unknown
-
2004
- 2004-06-01 JP JP2004163024A patent/JP4523799B2/ja not_active Expired - Lifetime
-
2005
- 2005-05-06 AR ARP050101848A patent/AR048891A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL129300A (en) | Liquid pharmaceutical composition comprising an hiv protease inhibitor or a combination of hiv protease inhibitors in a pharmaceutically acceptable organic solvent | |
IL110752A0 (en) | Pharmaceutical composition for an hiv protease inhibitor | |
IL109503A0 (en) | Hiv protease inhibitors and pharmaceutical compositions containing them | |
TJ339B (en) | A compound pharmaceutical composition and method for hiv protease inhibitors | |
HUP9900964A3 (en) | Protease inhibitors and pharmaceutical compositions containing these compounds | |
HUP0105077A3 (en) | Serine protease inhibitors and pharmaceutical compositions containing them | |
IL128664A (en) | Heterocyclic metalloprotease inhibitors and pharmaceutical compositions comprising them | |
HUP0100669A3 (en) | Peptide derivatives as serine protease inhibitors, their use and pharmaceutical compositions comprising thereof | |
IL120311A0 (en) | Serine protease inhibitors and pharmaceutical compositions containing them | |
HUP0201591A3 (en) | Pharmaceutical formulations comprising an hiv protease inhibitor | |
HUP9902256A3 (en) | Amidino protease inhibitors and pharmaceutical compositions containing them | |
HUP9900390A3 (en) | Serine protease inhibitors, and pharmaceutical compositions containing them | |
ZA973062B (en) | New pharmaceutical formulation of a thrombin inhibitor for parenteral use. | |
IL108327A (en) | Pharmaceutical composition comprising 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent | |
IL110724A (en) | Retroviral protease inhibitors and pharmaceutical compositions containing them | |
AU9640698A (en) | Pharmaceutical combination of a cyclooxigenase-2 inhibitor and acetaminophen or an opiate | |
AU4641097A (en) | New pharmaceutical parenteral formulation of a thrombin inhibitor | |
HUP0001976A3 (en) | Antiviral protease inhibitors and pharmaceutical compositions | |
AU3146997A (en) | Pediatric formulation for hiv protease inhibitors | |
IL114208A0 (en) | Combinations of compounds pharmaceutical compositions containing them and their use as hiv protease inhibitors | |
IL111467A0 (en) | Pharmaceutical compositions comprising 7 beta -substituted -4-aza 5 alpha -cholestan-3-ones and 5 alpha reductase 1 inhibitors | |
IL125098A0 (en) | Peptidomimetic inhibitors of hiv protease and pharmaceutical compositions containing them | |
GB9818841D0 (en) | Pharmaceutical use of protease inhibitors | |
GB9613109D0 (en) | Pediatric formulation for HIV protease inhibitors | |
HUP0001380A3 (en) | Isoquinoline derivatives as hiv protease inhibitors, and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |